Epstein-Barr Virus Associated Lymphoproliferative Disorder

Epstein-Barr virus associated lymphoproliferative disorder is a group of rare conditions where infection with the common Epstein-Barr virus causes certain white blood cells to multiply excessively, potentially leading to diseases ranging from benign conditions to aggressive cancers.

Table of contents

• What is Epstein-Barr Virus Associated Lymphoproliferative Disorder?
• Understanding the Epstein-Barr Virus
• How the Disorder Develops
• Types of Disorders
• Signs and Symptoms
• Who Is at Risk?
• Treatment Approaches

What is Epstein-Barr Virus Associated Lymphoproliferative Disorder?

Epstein-Barr virus associated lymphoproliferative disorder, also known as EBV-associated lymphoproliferative disease or EBV+ LPD, is a group of disorders where one or more types of lymphoid cells (a type of white blood cell) become infected with the Epstein-Barr virus. This infection causes these cells to divide excessively, which is linked to the development of various conditions ranging from non-cancerous to pre-cancerous and cancerous disorders^[2].

EBV-associated lymphoproliferative diseases, EBV+ LPD, EBV-positive lymphoproliferative disorder

The lymphoid cells that can be affected include B cells, T cells, NK cells (natural killer cells), and histiocytic-dendritic cells. Each of these cell types plays a different role in the body’s immune system^[2].

While the virus is usually involved in causing or worsening these disorders, in some cases it may simply be present without actually contributing to the disease. The disorders can include the well-known condition that occurs during initial infection with EBV, called infectious mononucleosis, as well as many other conditions that may develop afterward^[2].

Understanding the Epstein-Barr Virus

Epstein-Barr virus, also known as human herpesvirus 4 (HHV-4), is one of eight known herpesviruses that affect humans. It is extremely common, with more than 95% of the human population carrying the virus at some point in their lives^[1][4].

Most people are infected with EBV during the first decades of life and remain without symptoms. After the initial infection, EBV does not leave the body but instead remains dormant (inactive or sleeping) in memory B cells for the rest of a person’s life^[3][8].

The virus spreads primarily through bodily fluids, especially saliva. This is why infectious mononucleosis is sometimes called the “kissing disease.” The virus can also spread through coughing, sneezing, sharing drinks or utensils, and through blood and other body fluids^[3].

How the Disorder Develops

When EBV enters the body, it follows a specific pattern. First, the virus infects the lining of the back of the throat and salivary glands. From there, it infects nearby B cells, which are white blood cells that help fight infections. These infected B cells then spread through the bloodstream throughout the body^[3].

The infection causes the B cells to multiply, leading to swelling of lymphoid tissues, including the lymph glands. The B cells can also infect T cells that they come into contact with^[3].

In most healthy people, the immune system keeps EBV-infected cells under control through specialized immune cells called EBV-specific cytotoxic T cells. However, when the immune system is weakened or not functioning properly, EBV-infected B cells, T cells, or NK cells can grow out of control, resulting in lymphoproliferative disorders^[8][14].

Types of Disorders

EBV-associated lymphoproliferative disorders are classified based on which type of lymphoid cell is infected. The two main categories are B-cell disorders and T-cell/NK-cell disorders^[3][7].

EBV-associated B-cell lymphoproliferative disorders include several conditions. These range from Burkitt lymphoma and classical Hodgkin lymphoma to disorders that occur after organ transplantation called post-transplant lymphoproliferative disorder. They also include disorders related to HIV infection^[3][7].

EBV-associated T-cell and NK-cell lymphoproliferative disorders include conditions such as peripheral T-cell lymphoma, chronic active EBV infection of T-cell and NK-cell types, angioimmunoblastic T-cell lymphoma, and extranodal nasal NK/T-cell lymphoma. EBV has been most directly linked to the last two types^[3][7].

Most cases of EBV-associated lymphoproliferative disorders reported to date have involved B cells or T cells. In Asia and South America, the majority of chronic active EBV cases involve T cells or NK cells, while in the United States, B cells are more often involved^[5][15].

Signs and Symptoms

The symptoms of EBV-associated lymphoproliferative disorders vary widely depending on the specific condition and which cells are affected.

For disorders resembling infectious mononucleosis or chronic active EBV infection, symptoms can include fever lasting more than three months, sore throat, swollen lymph nodes (particularly in the neck), enlargement of the spleen and liver, fatigue, and rash^[5][15].

Some patients may develop more serious complications including abnormal blood cell counts, organ infiltration by infected cells, or progression to lymphoma (a type of cancer). In chronic active EBV infection, patients may have persistent or recurring symptoms similar to infectious mononucleosis for at least three months, along with markedly elevated levels of EBV DNA in the blood^[5][15].

Certain skin manifestations can also occur, particularly in disorders involving T cells or NK cells. These can include ulcers in the mouth or on the skin^[3][7].

Who Is at Risk?

EBV-associated lymphoproliferative disorders are rare conditions that typically occur in people with weakened immune systems. Several factors can increase the risk of developing these disorders^[3][7].

People who have received organ transplants and are taking medications to suppress their immune system are at increased risk. This includes both solid organ transplants (such as kidney or liver) and hematopoietic stem cell transplantation (bone marrow transplant)^[8][14].

Individuals with HIV infection and AIDS are also at higher risk because their immune systems are compromised. Other forms of immune deficiency, whether inherited or acquired, can increase susceptibility to these disorders^[3][7].

Age-related weakening of the immune system, called immune senescence, can also be a risk factor, particularly in older adults^[3][7].

There appear to be geographic and genetic differences in who develops these disorders. Most cases of chronic active EBV infection have been reported in East Asia and parts of South America, suggesting that genetic and environmental factors may play a role^[5][15].

Treatment Approaches

Treatment for EBV-associated lymphoproliferative disorders depends on the specific type of disorder, its severity, and the patient’s overall health condition. The main goal is to restore balance between the growing EBV-infected cells and the body’s immune response^[8][14].

For patients who developed the disorder after organ transplantation, the first step is often to reduce the amount of immune-suppressing medication they are taking. This allows the patient’s own immune system to better control the EBV-infected cells. However, this approach must be carefully balanced against the risk of organ rejection^[8][14].

A medication called rituximab, which is a type of antibody that targets B cells, has shown effectiveness in treating some EBV-associated lymphoproliferative disorders. It can be used alone when the disease is detected early or in combination with chemotherapy for more advanced cases^[8][14].

For severe cases that do not respond to other treatments, chemotherapy may be necessary. However, chemotherapy can have significant side effects and may not be suitable for all patients^[8].

A promising approach involves using cytotoxic T lymphocytes (CTL), which are immune cells specifically trained to recognize and kill EBV-infected cells. These cells can come from the patient themselves, from the organ donor (in transplant cases), or from specially prepared cell banks that provide partially matched cells from third-party donors^[8][10][11].

For chronic active EBV infection, particularly cases involving T cells or NK cells, hematopoietic stem cell transplantation (bone marrow transplant) is currently considered the only curative treatment. Various other therapies may be used to relieve symptoms, but only stem cell transplantation can eliminate the disorder completely^[5][15].

Early detection is important for better outcomes. For high-risk patients, such as those who have received transplants, regular monitoring of EBV DNA levels in the blood can help identify problems early, when treatment is more likely to be successful^[8][14].